Horizon Technology Finance Corp reported Q2 results reflecting challenges in net income against the backdrop of market volatility affecting its tech and life sciences debt portfolio. The company continues to focus on active portfolio management in biotechnology, medical devices, and software sectors, leveraging secured notes and a targeted stock repurchase program to optimize capital structure. Cybersecurity risk oversight remains integral, supporting operational resilience. Horizon faces inherent sector concentration risks compounded by recent earnings pressures, with growth hinging on demand for non-bank debt financing in innovation-driven industries.